Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.

Pediatr Blood Cancer 2007 Jan;48(1):93-100

CLIP-Childhood Leukemia Investigation Prague, Prague, Czech Republic.

Background: The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of clone-specific immunoglobulin/T-cell receptor (Ig/TCR) rearrangements have documented the feasibility and practicality of this technique. This approach has also been disputed due to the occurrence of clonal evolution and generally high MRD levels prior to HSCT.

Procedure: In our prospective study, MRD before and after HSCT was monitored using quantitative real-time PCR in a cohort of 36 children with ALL consecutively transplanted in our center between VIII/2000 and VII/2004.

Results: In 25 of 36 patients, MRD level prior HSCT was assessed. Seventeen patients were classified as MRD-negative and eight were MRD-positive up to 9 x 10(-2). In MRD-positive subgroup, seven events (six relapses) occurred post-transplant in striking contrast to only one relapse in MRD-negative subgroup (event-free survival (EFS) log-rank P < 0.0001). MRD proved to be the only significant prognostic factor in a multivariate analysis (P < 0.0001). Adoptive immunotherapy including donor lymphocyte infusions in patients with adverse dynamics of MRD after HSCT had only limited and/or temporary effect. Clonal evolution did not present a problem precluding MRD monitoring in any of patients suffering a post-transplant relapse.

Conclusions: We show that MRD quantitation using clonal Ig/TCR rearrangements successfully assesses the risk in pediatric ALL patients undergoing allogeneic HSCT. As our ability to treat detectable MRD levels after HSCT is very limited, alternative strategies for MRD-positive patients prior HSCT are necessary.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.20794DOI Listing
January 2007
28 Reads

Publication Analysis

Top Keywords

mrd
9
prior hsct
8
clonal evolution
8
cell transplantation
8
stem cell
8
lymphoblastic leukemia
8
ig/tcr rearrangements
8
pediatric patients
8
prognostic factor
8
hsct limited
8
hematopoietic stem
8
acute lymphoblastic
8
minimal residual
8
allogeneic hematopoietic
8
residual disease
8
mrd levels
8
mrd hsct
8
hsct
7
patients
7
mrd-positive subgroup
4

References

(Supplied by CrossRef)

Knechtli et al.
Blood 1998

Bader et al.
Leukemia 2002

van der Velden et al.
Leukemia 2001

van der Velden et al.
Leukemia 2003

Krejci et al.
Bone Marrow Transplant 2003

Imashuku et al.
Bone Marrow Transplant 2003

Szczepanski et al.
Blood 2002

Pongers-Willemse et al.
Leukemia 1999

Szczepanski et al.
Blood 1999

van Dongen et al.
Leukemia 2003

van der Velden et al.
Leukemia 2002

Similar Publications